Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Occlusal Splint and Botulinum Toxin for Bruxism
NCT06593821Completed
- Sponsor
- Zonguldak Bülent Ecevit University
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of neuronox in bruxism and masseter hypertrophy (4 arms), sponsored by Zonguldak Bülent Ecevit University. Primary endpoints: Masseter muscle thickness at 6 months, Maximum mouth opening at 6 months and 1 more. Started Apr 2023; status: completed.
02
Drugs
neuronox
03
Conditions
bruxismmasseter hypertrophy
Beyond the preview
Go deeper on NCT06593821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593821.